Insights On Upstream Manufacturing

  1. Integrated Upstream And Downstream Strategies For Robust Manufacturing 2/5/2026

    Process robust mAb production requires understanding scale dependent cell environments, leveraging predictive models, and pursuing data driven control to minimize variability and optimize quality.

  2. Rapid Discovery Of CD200R1 Antagonist VHHs Via Single B Cell Technology 2/4/2026

    Here, we used single B cell antibody discovery to rapidly identify a diverse set of potent, high-affinity, neutralizing VHH from immunized llamas against CD200R1, an emerging therapeutic immune checkpoint target.

  3. Bispecific Antibodies Unleashed 2/4/2026

    Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.

  4. Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs 2/4/2026

    Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.

  5. Flexible Cell Culture Media For High Titer Production Of AAV In HEK 293 2/4/2026

    To maximize the results of viral titer and full capsids, it's necessary to undertake systematic process development and optimization of AAV production. The choice of cell culture medium is foundational.

  6. Application Of A Dual Spiking Strategy In Viral Clearance Studies 2/3/2026

    Explore how an alternative spiking strategy can streamline viral clearance studies, reduce material demands, and maintain compliance while addressing the challenges posed by MLV and MMV.

  7. Engineering Reliability In Cell Therapy Manufacturing 2/3/2026

    A cell therapy manufacturing model built on precision planning, digital execution, lifecycle‑ready CMC systems, and transparent collaboration to achieve high reliability and reduce variability across programs.

  8. Fab Antibody Fragment Titer Improvement 2/2/2026

    Learn how systematic screening of unique expression strains and plasmid combinations can overcome low protein yields, achieving active Fab titers over 4 g/L.

  9. How Do You Protect Incubation Workflows From Contamination And Downtime? 1/29/2026

    Active HEPA filtration protects cell cultures by restoring air quality within minutes. Learn how continuous purification reduces contamination risks and ensures reliable, reproducible research.

  10. Enhancing Biopharma ROI With In-House Long-Read Sequencing 1/29/2026

    Long-read sequencing is redefining research by enabling clearer insights into complex genetic regions. Learn how this technology strengthens data confidence and accelerates modern R&D workflows.